Santen Pharmaceutical (OTCMKTS:SNPHY) Trading Down 2.2% – Here’s Why

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY)’s stock price fell 2.2% during trading on Friday . The company traded as low as $11.10 and last traded at $11.10. 2,069 shares were traded during trading, a decline of 88% from the average session volume of 17,423 shares. The stock had previously closed at $11.3550.

Santen Pharmaceutical Stock Down 2.2%

The business has a fifty day moving average of $10.99 and a 200-day moving average of $10.64.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.